A Spanish study explored the loss of health-related quality of life (HRQoL) in children younger than two years after a respiratory syncytial virus (RSV) infection. Results showed an HRQoL loss of 38%, 32% and 9% during the first, second and third week after the diagnosis and a median cost of ~€600 per treated child. This type of socioeconomic evaluation could help prioritise the development of an RSV vaccine. The Respiratory Syncytial Virus (RSV) is a…